• Home
  • NEW DAY MEDICINE
  • 6 (38) 2021
  • 28 -6 (38) 2021 — Boyko E.V., Khudaiberdieva D.A. — ON THE ISSUE OF THE SIGNIFICANCE OF METHODS OF DIAGNOSIS OF PROSTATE CANCER

28 -6 (38) 2021 — Boyko E.V., Khudaiberdieva D.A. — ON THE ISSUE OF THE SIGNIFICANCE OF METHODS OF DIAGNOSIS OF PROSTATE CANCER

ON THE ISSUE OF THE SIGNIFICANCE OF METHODS OF DIAGNOSIS OF PROSTATE CANCER

Boyko E.V., Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, MHRUz

Khudaiberdieva D.A. Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, MHRUz

Resume

Widespread prevalence, difficult diagnosis, social and economic significance of prostate cancer require increasing the efficiency of diagnostics of prostate pathologies. The sensitivity, specificity and accuracy of the finger rectal examination, determination of the prostate-specific antigen level, transrectal ultrasound examination of the prostate in the gray window mode, with ultrasound angiography, Doppler and magnetic resonance imaging of the prostate have been determined.

Key words: prostate cancer, significance of diagnostic methods.

First page

153

Last page

159

For citation: Boyko E.V., Khudaiberdieva D.A. ON THE ISSUE OF THE SIGNIFICANCE OF METHODS OF DIAGNOSIS OF PROSTATE CANCER //New Day in Medicine 6(38)2021 153-159 https://cutt.ly/yYp3RGe

LIST OF REFERENCES:

  1. Tillyashaykhov M.N., Ibragimov SH.N., Dzhanklich S.M. Sostoyaniye onkologicheskoy pomoshchi naseleniyu Respubliki Uzbekistan v 2019 godu. – Tashkent, 2020. – 124 s.
  2. Aleksandrov V.P., Karelin M.I. Rak predstatel’noy zhelezy. SPb.: izdatel’skiy dom SPbMAPO. – 2004. 148 s
  3. Apolikhin O.I., Sivkov A.V., Moskaleva N.G. i soavt. Analiz uronefrologicheskoy zabolevayemosti i smertnosti v Rossiyskoy Federatsii za desyatiletniy period (2002- 2012 gg.) po dannym ofitsial’noy statistiki // Eksperimental’naya i klinicheskaya urologiya. – 2014. – №2. S 4-12.
  4. Kaprin A.D., Kostin A.A., Kul’chenko N.G. i soavt. Skrining raka predstatel’noy zhelezy na osnove mnogofaktornogo analiza // Vestnik meditsinskogo instituta “REAVIZ”: reabilitatsiya, vrach i zdorov’ye. – 2014. – №4. – S.38-42.
  5. Katibov M.I., Voytko D.A. Selektivnyy skrining kak novyy podkhod k povysheniyu effektivnosti diagnostiki i lecheniya raka predstatel’noy zhelezy. // Sbornik tezisov 10-go yubileynogo kongressa professional’noy assotsiatsii andrologov Rossii. – 2015. – S. 55
  6. Pushkar’ D.Yu., Kolontarev K.B., Alekseyev B.YA. i soavt. Urologiya. Rossiyskiye klinicheskiye rekomendatsii. Moskva. – 2016. 492s.;
  7. Rodoman V.Ye., Avdoshin V.P., Kolesnikov G.P. Zabolevaniya predstatel’noy zhelezy. M.: Meditsinskoye informatsionnoye agenstvo. – 2009. – 667s.
  8. Chissov V.I., Starinskiy V.V., Petrov G.V. Zlokachestvennyye novoobrazovaniya v Rossii v 2010 godu (zabolevayemost’ i smertnost’) M.: FGBU «MNIOI im. P.A. Gertsena» Minzdravsotsrazvitiya Rossii. 2012. – s100
  9. Berry SL, Boczkowski A, Ma R, Mechalakos J, Hunt M. Interobserver variability in radiation therapy plan output: Results of a single-institution study. // Pract Radiat Oncol. 2016 Nov-Dec;6(6):442-449. doi: 10.1016/j.prro.2016.04.005. Epub 2016 May 8. PMID: 27374191; PMCID: PMC5099085
  10. Collins M.M., Meigs J.B., Barry M.J. et al. Prevalence and correlates of prostatitis in the health professional’s follow-up study cohort // J. Urol. – 2020. – 167(№ 3). – P. 1363-1366.;
  11. Hamdi Y, Abdeljaoued-Tej I, Zatchi AA, Abdelhak S, Boubaker S, Brown JS, Benkahla A. Cancer in Africa: The Untold Story. // Front Oncol. 2021 Apr 15;11:650117. doi: 10.3389/fonc.2021.650117. PMID: 33937056; PMCID: PMC8082106.;
  12. Mariotti GC, Costa DN, Pedrosa I, et al. Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients. // UrolOncol. – 2016. – №34(9). – р.416.e9-e14
  13. Mukherjee S, Sudandiradoss C. Transcriptomic analysis of castration, chemo-resistant and metastatic prostate cancer elucidates complex genetic crosstalk leading to disease progression. // FunctIntegr Genomics. 2021 Jul;21(3-4):451-472. doi: 10.1007/s10142-021-00789-6. Epub 2021 Jun 29. PMID: 34184132
  14. Nelms B, Stambaugh C, Hunt D, Tonner B, Zhang G. Methods, software and datasets to verify DVH calculations against analytical values: Twenty years late(r). // Med Phys. 2015 Aug;42(8):4435-48. doi: 10.1118/1.4923175. PMID: 26233174
  15. Phua T.J. The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective. // Medicines (Basel). 2021 Jun 11;8(6):30. doi: 10.3390/medicines8060030. PMID: 34208086
  16. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. // CA Cancer Journal for Clinicians. – 2012. – vol. 62. – no. 1. – pp. 10-29
  17. Taylor T, Richmond N. A UK wide study of current prostate planning practice. // Br J Radiol. 2020 Jul;93(1111):20200142. doi: 10.1259/bjr.20200142. Epub 2020 Apr 24. PMID: 32267721; PMCID: PMC7336059
  18. Villaggi E, Hernandez V, Fusella M, Moretti E. Plan quality improvement by DVH sharing and planner’s experience: Results of a SBRT multicentric planning study on prostate. // Phys Med. 2019 Jun;62:73-82. doi: 10.1016/j.ejmp.2019.05.003. Epub 2019 May 10. PMID: 31153401;
  19. Waddell AR, Huang H, Liao D. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers. // Cancers (Basel). 2021 Jun 8;13(12):2872. doi: 10.3390/cancers13122872. PMID: 34201346
  20. Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018 Sep 1;32(17-18):1105-1140. doi: 10.1101/gad.315739.118. PMID: 30181359; PMCID: PMC6120714.

file

download